2-Cyclopropyl-propylamine -p-toluenesulfonate salt
| Code | Size | Price |
|---|
| CDX-C0145-G002 | 2 g | £190.00 |
Quantity:
| CDX-C0145-G010 | 10 g | £714.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
Ambient
Storage:
+4 °C
Documents
Further Information
Appearance:
Solid.
CAS:
172947-14-7
EClass:
32160000
Form (Short):
liquid
Handling Advice:
Protect from light and moisture.
InChi:
InChI=1S/C7H8O3S.C6H13N/c1-6-2-4-7(5-3-6)11(8,9)10;1-6(2,7)5-3-4-5/h2-5H,1H3,(H,8,9,10);5H,3-4,7H2,1-2H3
InChiKey:
RGWMDWPKOOWZSF-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 172947-14-7. Formula: C6H13N . C7H8O3S. MW: 271.38. Synthetic. Building block for synthesis.
MDL:
MFCD01090985
Molecular Formula:
C6H13N . C7H8O3S
Molecular Weight:
271.38
Package Type:
Vial
Product Description:
Building block for synthesis.
Purity:
>98% (Elemental Analysis)
SMILES:
CC(C)([NH3+])C1CC1.CC1=CC=C(C=C1)S([O-])(=O)=O
Solubility Chemicals:
Soluble in chloroform.
Source / Host:
Synthetic.
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at +4°C.
Related Products
| Product Name | Product Code | Supplier | 2-Bromoacrolein | CDX-B0251 | Chemodex | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N-(3-Bromopropyl)-7-nitro-2,1,3-benzoxadiazol-4-amine | CDX-B0268 | Chemodex | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 2-Chlorocyclohepta-2,4,6-trienone | CDX-C0181 | Chemodex | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||